Reply to: Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms
Clin Exp Rheumatol
.
2019 Jul-Aug;37 Suppl 119(4):153.
Epub 2019 Oct 3.
Authors
Wai Chung Yong
1
,
Sikarin Upala
2
,
Anawin Sanguankeo
3
Affiliations
1
Department of Internal Medicine, Greenfield Family Medicine, Baystate Franklin Medical Center, Greenfield, MA, USA.
2
Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
3
Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. asangua1@jhmi.edu.
PMID:
31587691
No abstract available
Publication types
Letter
Comment
MeSH terms
Anti-Bacterial Agents
Drug Therapy, Combination
Helicobacter pylori*
Humans
Scleroderma, Systemic*
Substances
Anti-Bacterial Agents